The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010

被引:29
|
作者
Younossi, Z. M. [1 ,2 ]
Stepanova, M. [2 ]
Mishra, A. [1 ]
Venkatesan, C. [1 ]
Henry, L. [2 ]
Hunt, S. [1 ,2 ]
机构
[1] Inova Fairfax Hosp, Dept Med, Falls Church, VA USA
[2] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
关键词
QUALITY-OF-LIFE; DUAL ELIGIBLES; COST; EPIDEMIOLOGY; VIRUS;
D O I
10.1111/apt.12485
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundAs baby boomers age, chronic hepatitis C (CHC) will become increasingly important in Medicare eligible group. AimTo evaluate trends in Medicare resource utilisation for CHC. MethodsWe analysed the Medicare in-patient and out-patient data from 2005 to 2010. For each patient, all claims with CHC as a principal diagnosis were added up and yearly CHC-related spending was calculated. ResultsA total of 48880 out-patient claims for 21655 CHC patients and 4884 hospital admission claims for 3092 patients were included. The number of in-patient (1.5-1.6/year) or out-patient (2.2-2.3/year) visits per patient did not change over time, nor did the demographic characteristics of the CHC population. The majority of this population was eligible for Medicare based on disability and the average number of diagnoses per in-patient claim (from 8.11 in 2005 to 8.60 in 2010) and per out-patient claim (from 2.18 in 2005 to 2.71 in 2010) increased (both P<0.0001). The average total yearly spending per patient increased in the out-patient setting from $488 in 2005 to $584 in 2010 (P=0.0132) and did not change in the in-patient setting (from $22245 in 2005 to $23383 in 2010, P=0.14). In the multivariate analysis, the number of diagnoses and conditions per claim and the number of in-patient or out-patient procedures per year were the important independent predictors of increased resource utilisation. ConclusionsMost Medicare beneficiaries with chronic hepatitis C who sought in-patient or out-patient care in 2005-2010 had received Medicare for disability. Although the total resource utilisation did not change, the proportion of patient's responsibility increased.
引用
收藏
页码:1065 / 1075
页数:11
相关论文
共 50 条
  • [31] Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C
    Buti, M
    San Miguel, R
    Brosa, M
    Cabasés, JM
    Medina, M
    Casado, MA
    Fosbrook, L
    Esteban, R
    JOURNAL OF HEPATOLOGY, 2005, 42 (05) : 639 - 645
  • [32] Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit
    Alvaro-Meca, Alejandro
    Jimenez-Sousa, Maria A.
    Boyer, Alexandre
    Medrano, Jose
    Reulen, Holger
    Kneib, Thomas
    Resino, Salvador
    BMC INFECTIOUS DISEASES, 2016, 16
  • [33] Impact of chronic hepatitis C on mortality in cirrhotic patients admitted to intensive-care unit
    Alejandro Álvaro-Meca
    María A. Jiménez-Sousa
    Alexandre Boyer
    José Medrano
    Holger Reulen
    Thomas Kneib
    Salvador Resino
    BMC Infectious Diseases, 16
  • [34] The Impact of Nurse Practitioner and Physician Assistant Workforce Supply on Chronic Disease-Related ED Visits and In-Patient Hospitalizations of Medicaid Beneficiaries in New York State
    Norful, Allison
    de Jacq, Krystyna
    Liu, Jianfang
    Poghosyan, Lusine
    NURSING RESEARCH, 2019, 68 (02) : E76 - E76
  • [35] Thyroid dysfunction in Turkish patients with chronic hepatitis C receiving peginterferon plus ribavirin in the period of 2005-2010
    Barut, Sener
    Gunal, Ozgur
    Erkorkmaz, Unal
    Yildiz, Feyza
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2012, 16 (05): : 448 - 451
  • [36] Association between the "puffy-hand sign" and chronic hepatitis C in a geriatric patient
    Studdiford, James S.
    Stonehouse, Amber R.
    Anandanadesan, Rathai
    Scott, Kevin C.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2007, 55 (10) : 1694 - 1695
  • [37] Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection
    Gatti, Danielle C.
    Cha, Agnes
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (23) : 2062 - 2065
  • [38] Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes
    Younossi, Zobair M.
    Stepanova, Maria
    Sulkowski, Mark
    Naggie, Susanna
    Puoti, Massimo
    Orkin, Chloe
    Hunt, Sharon L.
    JOURNAL OF INFECTIOUS DISEASES, 2015, 212 (03): : 367 - 377
  • [39] Effects of direct-acting antivirals on end-stage liver disease and mortality among Florida Medicaid beneficiaries with chronic hepatitis C
    Huang, Pei-Lin
    Chang, Shao-Hsuan
    Cabrera, Roniel
    Wilson, Debbie
    Park, Haesuk
    JOURNAL OF HEPATOLOGY, 2024, 80 : S658 - S658
  • [40] Impact of Pegylated Interferon and Ribavirin on Morbidity and Mortality in Patients with Chronic Hepatitis C and Normal Aminotransferases in France
    Deuffic-Burban, Sylvie
    Babany, Gerard
    Lonjon-Domanec, Isabelle
    Deltenre, Pierre
    Canva-Delcambre, Valerie
    Dharancy, Sebastien
    Louvet, Alexandre
    Roudot-Thoraval, Francoise
    Mathurin, Philippe
    HEPATOLOGY, 2009, 50 (05) : 1351 - 1359